NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

MLA

Marlyn J. Mayo, et al. “NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial.” Hepatology Communications, vol. 2, no. 9, Sept. 2018, pp. 1037–50. EBSCOhost, https://doi.org/10.1002/hep4.1209.

APA

Marlyn J. Mayo, Alan J. Wigg, Barbara A. Leggett, Hays Arnold, Alexander J. Thompson, Martin Weltman, Elizabeth J. Carey, Andrew J. Muir, Lei Ling, Stephen J. Rossi, & Alex M. DePaoli. (2018). NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial. Hepatology Communications, 2(9), 1037–1050. https://doi.org/10.1002/hep4.1209

Chicago

Marlyn J. Mayo, Alan J. Wigg, Barbara A. Leggett, Hays Arnold, Alexander J. Thompson, Martin Weltman, Elizabeth J. Carey, et al. 2018. “NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial.” Hepatology Communications 2 (9): 1037–50. doi:10.1002/hep4.1209.